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BACKGROUND:  Primary  hepatic  carcinoid  tumors  (PHCT)  are  rare  entities;  they  are  even  rarer  than  extra-
hepatic  neuroendocrine  gastrointestinal  tumors  with  only  about  95 cases  reported  in  the  literature.  An
extrahepatic  primary  tumor  must  be  excluded  to conﬁrm  the  diagnosis  of  PHCT.
CASE PRESENTATION:  We  report  a case  of  a  42-year-old  male  patient  with  a  primary  hepatic  neuroen-
docrine  carcinoma,  who  successfully  underwent  living  donor  liver  transplantation  from  his  70 years  old
mother  with  10  years  follow-up.  Both  donor  and  recipient  are  still  alive  and  in  the  good  health.
CONCLUSION: Living  liver  donation  from  elderly  donors  for  the  patients  with  irresectable  neuroendocrinerimary  hepatic neuroendocrine carcinoma
lderly living donors
liver  malignancies  can be  as  safe  as  deceased  donation  or liver  donation  from  young  donors  (age  < 50).
Living  donation  from  elderly  donors  might  signiﬁcantly  expand  the  donor  pool  for patients  with  liver
neuroendocrine  tumors  (NET)  and  potentially  reduce  waiting  list  mortality.  Especially  young  patients
with  irresectable  NET  can  beneﬁt  from  this  option.  However,  case–control  studies  are  needed  to verify
the  advantage  of living  liver  transplantation  (LDLT)  for the  patients  with  irresectable  liver NET  and  to
deﬁne  selection  criteria  for these  patients.
gical  © 2011 Sur
. Introduction
Primary hepatic carcinoid tumors (PHCT) are even rarer than
xtrahepatic gastrointestinal neuroendocrine tumors with only
bout 95 cases reported in the literature.1 This entity is not included
o a current WHO  classiﬁcation of neuroendocrine tumors (NET).
here are few or none neuroendocrine cells in the liver compared
o other organs, therefore an exact derivation of these tumors
emains unclear. Nevertheless, there are several theories for the
rigin of PHCT. According to ﬁrst hypothesis the neuroendocrine
umors of the liver arise from ectopic pancreatic cells. However, the
ajority of these tumors showed no pancreas speciﬁc endocrine
unction.2 Some investigators suggest that the origin of PHCT can
e omnipotential hepatic cells.3 Alternatively, the endocrine hep-
tic tumors arise from endocrine cells scattered in the intrahepatic
iliary epithel.4,5 These cells are also observed in hepatobiliary cys-
adenomas. Case reports concerning NET of the extrahepatic ducts
onﬁrm this hypothesis.6–11 It is supposed, that chronic inﬂam-
ation in the biliary system may  result to the development of
euroendocrine tumor by initiating intestinal metaplasia.12
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2. Presentation of case
A 42-year-old male patient was admitted at the end of August
2000 to our hospital for evaluation of hepatomegaly. The symp-
toms such as light abdominal distension and fever accompanied
with diarrhea started three weeks ago and were intermittent.
Liver function tests showed a serum bilirubin of 1.6 mg/dl (normal
<1.2 mg/dl), gamma-glutamyl transferase (GGT) of 504 U/l (nor-
mal <55 U/l), and alkaline phosphatase (AP) of 447 U/l  (normal
60–180 U/l), carcinoembryonic antigen (CEA) 9.4 (normal <5 g/l),
CA 19-9 66 kU/l (55 kU/l) whereas alanin-aminotransferase (ALT),
aspartate-aminotransferase (AST), alpha-fetoprotein (AFP), CA-
125, serotonin and 5-hydroxyindoleacetic acid (5-HIAA) in urine
were all normal.
Computed tomography (CT) and magnetic resonance imaging
(MRI) demonstrated a large tumor of both left and right liver lobe
with compression and displacement of portal vein leaving only seg-
ments 2 and 4 were free of tumor. Other lesions or primary tumors
could not be found but there were enlarged lymph nodes of liver
hilus and retroperitoneum (Fig. 1).
A percutaneous ultrasound-guided biopsy was  taken and this
showed a NET, evidenced by staining with synaptophysin. Upper
Open access under CC BY-NC-ND license.and lower gastrointestinal endoscopy revealed no pathology. A
somatostatin scan showed pathologic uptake only in the liver with
moderate expression of serotonin receptors. Additional investiga-
tions such as bronchoscopy, head-MRI and the Double Contrast
-NC-ND license. 
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sFigs. 1 and 2. CT scans showing a hypo-(Fig. 1), partl
mall Bowel Enema did not show any evidence of a primary lesion
lsewhere. Because of the size of the tumor liver resection was
ot possible and the patient was placed on the waiting list for
T. Transarterial chemoembolization was carried out in two  ses-
ions before the liver transplantation. November 2000 the patient
nderwent living donor liver transplantation using right-lobe graft
rom his 70 years old mother with simultaneous appendectomy.
he recovery after the operation was uneventful. Histology and
mmunohistochemistry of the liver tumor conﬁrmed the ﬁndings
f preoperative biopsy and showed a 23 cm large inﬁltrative neu-
oendocrine carcinoma (NEC) with Ki-67 proliferation index of
0%. Inmunohistochemistry showed positive staining for synap-
ophysin and negative staining gastrin, serotonin, chromogranine,
nd neuron-speciﬁc enolase.
The  histology of the appendix revealed ﬁbrosis but no neopla-
ia. The investigated lymph nodules showed no malignancy. Initial
mmunosuppression with Tacrolimus was because of nephrotoxic
nd neurological side reactions replaced with Sandimmune and
ellCept.
igs. 3 and 4. CT image showing the subpleural lung lesion in the lower lobe (left) – h
howing the lung lesion localized in the middle of the right lower lobe (right) (Fig. 4).r-dense liver (Fig. 2) mass involving both liver lobes.
The patient remained disease free 7 years after the initial
surgery, evidenced by serial CT and somatostatin scanning. During
the follow up, the patient notiﬁed of disappearance of the initial
clinical symptoms.
A  follow up PET-CT scan in April 2008 revealed two nodular pul-
monary lesions, one nodule was  8.8 mm  in diameter in the right
lower lobe, in posterior basal segment, subpleural (Fig. 3), and
another nodule was  9.8 mm in diameter in the right lower lobe,
central basal (Fig. 4) all without activity in PET. It was decided by
an interdisciplinary panel to repeat CT scan in 6 months and the
next CT scan in October 2008 showed progression of the pulmonary
lesions but again no activity on PET scan.
According to the past medical history and progression of pul-
monary lesions in follow up CT scans we  decided to remove these
nodules to assess their dignity. The preoperative lung function tests
and extended laboratory tests were normal. Endoscopic surgery
was inappropriate, because the lesion in the right lower lobe central
basal was too deep to be thoracoscopically resected. Therefore, a
right thorakotomy was performed and the both pulmonary lesions
istopathologically metastasis of neuroendocrine carcinoma (Fig. 3) and CT image
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ere by wedge resection in toto removed. Subsequently a lym-
hadenectomy was performed.
A  histopathologic examination revealed a metastasis of NEC
or superﬁcial localized lung lesion. The histology of the second
odule localized in the depth of the lower right lobe showed mod-
rate chronic lung emphysema with chronic peribronchitis. There
ere no lymph node metastases. Immunohistochemical staining
or AFP, CD56, and chromogranin was negative. The fraction of
i-67-positive tumor cells was 20%. After surgery, the patient had
n uneventful recovery without complications. To date, no recur-
ent or metastatic disease has been identiﬁed. The patient and his
other remains symptom free and in good health.
. Discussion
An extrahepatic primary tumor must be excluded to con-
rm the diagnosis of PHCT. This requires extended preoperative
iagnostic. Finally, a pathological conﬁrmation of preoperative
iagnosis and long follow-up are necessary to differentiate this
ncommon type of tumors from other NET. There are no cer-
ain standards for the therapy of PHCT, presumably because the
xistence of this entity is still controversial. Surgery is only cura-
ive option for treatment of primary and secondary hepatic NET.13
iver transplantation (LT) is considered potentially curative treat-
ent for the patients with irresectable multiple, bilateral primary
nd secondary neuroendocrine liver malignancies.14–16 Unfortu-
ately, there are no randomized control studies concerning this
opic and only a small number of publications, because of rareness
f this type of tumors. There are only few case reports regarding
T for patients with PHCT. Colleges from of St. James’s Univer-
ity Hospital in the UK, reported two patients transplanted for
HCT within the period from 1994 to 2002, in the same inter-
al six patients with PHTC underwent liver resection. This is one
f the largest series of patients with PHCT reported in European
iterature.17
We  use the same principles for therapy of primary and sec-
ndary NET of the liver, because of the difﬁculties with diagnosis
nd unclear behavior of PHCT. With our case report, we  want to
mphasize a role of Living Donor Living Transplantation (LDLT)
or treatment of irresectable neuroendocrine liver malignancies as
urative approach.
We  achieved a remarkable long-term survival of patient who
nderwent LDLT using right-lobe graft from his 70 years old
other, for irresectable liver-NEC with high mitotic activity
Ki-67 > 20%). This conﬁrms that LDLT from elderly living donors
or irresectable neuroendocrine liver malignancies can be safe and
easible. Living liver donation from elderly donors becomes more
mportant therapy option for the patients with liver NET, because
f the increasing shortage of donor organs. LT can be a potentially
urative treatment in selected patients with irresectable primary
nd secondary neuroendocrine hepatic tumors. In case of PCHT, LT
an bring cure, even for the Patients with high proliferative index
f tumor cells.
.  ConclusionLiving liver donation from elderly donors for the patients with
rresectable neuroendocrine liver malignancies can be as safe as
eceased donation or liver donation from young donors (age < 50).
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Living  donation from elderly donors might signiﬁcantly expand the
donor pool for patients with liver NET and potentially reduce wait-
ing list mortality. Especially young patients with irresectable NET
can beneﬁt from option. However, case–control studies are needed
to verify the advantage of LDLT for the patients with irresectable
liver NET and to deﬁne selection criteria for these patients.
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